SlideShare una empresa de Scribd logo
1 de 20
Prepared by :

Mohammed A Qazzaz
In 1906 Dr. Alois Alzheimer was first to
describe Alzheimer's illness.



A progressive, degenerative illness that attacks
the brain and results in impaired memory,
thinking and behavior.
Memory loss that affects job skills.
Difficulty performing familiar tasks.
Problems with language .
Disorientation to time and place.
Poor or decreased judgment.
Problems with abstract thinking.
Misplacing things .
Changes in mood or behavior.
Changes in personality.
Forgetfulness .
Social withdrawal .
Hallucinations .
Seizures .
Death usually result from
malnutrition , infection ,
heart disease
AD is a pan ethnic , genetically heterogeneous disease
Less than 5% of patients have an early-onset familial disease ,
15-25% of patients have a late-onset familial disease and 75%
of patients have a sporadic disease .


10% of familial AD exhibits autosomal dominant inheritance ;
the reminder exhibits multifactorial inheritance .
Early-onset AD is a rare form of AD, affecting
only about 5 percent of all people who have
AD. It develops in people ages 30 to 60.



FAD is caused by a number of different gene
mutations on chromosomes 21, 14, and 1, and
each of these mutations causes
abnormal proteins to be formed.
Mutations on chromosome 21 cause the
formation of abnormal amyloid precursor
protein (APP).

A mutation on chromosome 14 causes
abnormal presenilin 1 to be made,


and a mutation on chromosome 1 leads to
abnormal presenilin 2.
Even if only one of these mutated genes is
inherited from a parent, the person will almost
always develop early-onset AD.

 This inheritance pattern is referred to as
“autosomal dominant” inheritance.

In other words, offspring in the same generation
have a 50/50 chance of developing FAD if one of
their parents had it.
developing after age 60. genetics of AD have found that
the mutations seen in early-onset AD are not involved in
this form of the disease.

Both familial AD and sporadic late-onset AD are strongly
associated with Apo lipoprotein E (APOE) gene found on
chromosome 19


APOE comes in several different forms, or alleles. Three
forms—APOE ε2, APOE ε3, and APOE ε4—occur most
frequently.
APOE ε4 occurs in about 40 percent of all people who
develop late-onset AD.

and is present in about 25 to 30 percent of the
population. People with AD are more likely to have an
APOE ε4 allele than people who do not develop AD.

However, many people with AD do not have an APOE
ε4 allele.
APP undergoes endoproteolytic cleavage in the to
produce a peptide of 40 amino acid
(Aβ40) the function of Aβ40 is unknown .


In contrast , cleavage of APP in the endoplasmic
reticulum produce a peptide of 42 or 43
Amino acid (Aβ42/ Aβ43) .and its neurotoxic
substance .
Patients with AD have a significant increase in
(Aβ42/ Aβ43) aggregates within the brain
Mutation in APP PSEN1 and PSEN2 increase the
production of (Aβ42/43) .

1% of all AD cases occur in patients with down
syndrome . Who overexpress APP.

The role of ε4 is unclear .
Cortical atrophy .

Neurodegeneration in cholinergic neurons of hippocampus .

Extracellular neuritic plaques .

Intraneuronal neurofibrillary tangles .

Amyloid deposits in the wall of cerebral arteries .
An AD plaque   An AD tangle
Beta-amyloid Plaques
Amyloid precursor protein (APP) is the
precursor to amyloid plaque.
1. APP sticks through the neuron
   membrane.
2. Enzymes cut the APP into
fragments of protein, including beta-
amyloid.
3. Beta-amyloid fragments come
together  in clumps to form plaques.
Mutation in PSEN1 are fully penetrant and usually cause rapidly
progressive disease with mean onset at 45 .


Mutation in APP are fully penetrant and usually cause a rate of AD
progression similar to that of late-onset AD with range onset of 45
to 75 .


Mutation in PSEN2 are not fully penetrant and usually cause
slowly progressive disease with onset ranging from 40 to 57 .
Increase the cholinergic activity



 •cholesterol-lowering drugs
 •anti-oxidants (vitamins) and folic
 acid
 •anti-inflammatory drugs
 •substances that prevent formation
 of beta-amyloid plaques
 •nerve growth factor to keep
 neurons healthy
Old age

Family history

Female gender

Down syndrome
Alzheimer disease

Más contenido relacionado

La actualidad más candente

Alzheimer disease
Alzheimer disease Alzheimer disease
Alzheimer disease Tarek Gouda
 
Alzheimer powerpoint
Alzheimer powerpointAlzheimer powerpoint
Alzheimer powerpointJohnSmith2B1G
 
Alzheimer's Disease and its pathophysiology
Alzheimer's Disease and its pathophysiologyAlzheimer's Disease and its pathophysiology
Alzheimer's Disease and its pathophysiologyAchyut Adhikari
 
Alzheimers presentation...........
Alzheimers presentation...........Alzheimers presentation...........
Alzheimers presentation...........Muhammad Kamran
 
Alzheimer’s disease ppt
Alzheimer’s disease pptAlzheimer’s disease ppt
Alzheimer’s disease pptFariha Shikoh
 
Alzheimer s disease_powerpoint_skinner_kassandra
Alzheimer s disease_powerpoint_skinner_kassandraAlzheimer s disease_powerpoint_skinner_kassandra
Alzheimer s disease_powerpoint_skinner_kassandraCMoondog
 
Alzheimer’s disease
Alzheimer’s diseaseAlzheimer’s disease
Alzheimer’s diseaseAkhil Joseph
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's diseaseIqra Altaf
 
Alzheimer’s Disease - Causes, Symptoms & Treatment
Alzheimer’s Disease - Causes, Symptoms & TreatmentAlzheimer’s Disease - Causes, Symptoms & Treatment
Alzheimer’s Disease - Causes, Symptoms & Treatmentakajay201988
 
Alzheimer’s disease 2
Alzheimer’s disease 2Alzheimer’s disease 2
Alzheimer’s disease 2HARSHITA
 
Pathophysiology and management of alzheimer's disease
Pathophysiology and management of alzheimer's diseasePathophysiology and management of alzheimer's disease
Pathophysiology and management of alzheimer's diseaseSoujanya Pharm.D
 
Alzheimer's Disease
Alzheimer's DiseaseAlzheimer's Disease
Alzheimer's DiseaseLavGoyal3
 
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...Lazoi Lifecare Private Limited
 

La actualidad más candente (20)

Alzheimer disease
Alzheimer disease Alzheimer disease
Alzheimer disease
 
Alzheimer powerpoint
Alzheimer powerpointAlzheimer powerpoint
Alzheimer powerpoint
 
Alzheimer's Disease and its pathophysiology
Alzheimer's Disease and its pathophysiologyAlzheimer's Disease and its pathophysiology
Alzheimer's Disease and its pathophysiology
 
Alzheimers presentation...........
Alzheimers presentation...........Alzheimers presentation...........
Alzheimers presentation...........
 
alzheimer
alzheimeralzheimer
alzheimer
 
Alzheimer’s disease ppt
Alzheimer’s disease pptAlzheimer’s disease ppt
Alzheimer’s disease ppt
 
Alzheimer s disease_powerpoint_skinner_kassandra
Alzheimer s disease_powerpoint_skinner_kassandraAlzheimer s disease_powerpoint_skinner_kassandra
Alzheimer s disease_powerpoint_skinner_kassandra
 
Alzheimer’s disease
Alzheimer’s diseaseAlzheimer’s disease
Alzheimer’s disease
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Alzheimer’s disease full
Alzheimer’s disease   fullAlzheimer’s disease   full
Alzheimer’s disease full
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Alzheimer’s Disease - Causes, Symptoms & Treatment
Alzheimer’s Disease - Causes, Symptoms & TreatmentAlzheimer’s Disease - Causes, Symptoms & Treatment
Alzheimer’s Disease - Causes, Symptoms & Treatment
 
Alzheimer’s disease 2
Alzheimer’s disease 2Alzheimer’s disease 2
Alzheimer’s disease 2
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Alzheimer's disease
Alzheimer's disease Alzheimer's disease
Alzheimer's disease
 
Alzheimers disease
Alzheimers diseaseAlzheimers disease
Alzheimers disease
 
Pathophysiology and management of alzheimer's disease
Pathophysiology and management of alzheimer's diseasePathophysiology and management of alzheimer's disease
Pathophysiology and management of alzheimer's disease
 
Alzheimer's Disease
Alzheimer's DiseaseAlzheimer's Disease
Alzheimer's Disease
 
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
 

Destacado

what is Alzheimer disease
what is Alzheimer diseasewhat is Alzheimer disease
what is Alzheimer diseaseMicrobiology
 
Coursera work: Understanding the Brain: The Neurobiology of Everyday Life
Coursera work: Understanding the Brain: The Neurobiology of Everyday LifeCoursera work: Understanding the Brain: The Neurobiology of Everyday Life
Coursera work: Understanding the Brain: The Neurobiology of Everyday Lifepaulabrillos
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer diseaseViksn Vik
 
Alzheimer\'s Disease
Alzheimer\'s DiseaseAlzheimer\'s Disease
Alzheimer\'s DiseaseMarquezSelene
 
New treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseNew treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseSarath Menon
 
Alzheimer awareness
Alzheimer awarenessAlzheimer awareness
Alzheimer awarenessDeepa Anil
 
Alzheimer disease and treatment
Alzheimer disease and treatment Alzheimer disease and treatment
Alzheimer disease and treatment Shourav Ahmed
 
Alzheimer Disease and Mind Function
Alzheimer Disease and Mind FunctionAlzheimer Disease and Mind Function
Alzheimer Disease and Mind FunctionUNIMAS
 
Presentacion alzheimer psp 1ºev.
Presentacion alzheimer psp 1ºev.Presentacion alzheimer psp 1ºev.
Presentacion alzheimer psp 1ºev.2721992
 
Proteins, medical utility, diagnosis and treatment in Alzheimer disease
Proteins, medical utility, diagnosis and treatment in Alzheimer disease Proteins, medical utility, diagnosis and treatment in Alzheimer disease
Proteins, medical utility, diagnosis and treatment in Alzheimer disease Juan Sebastian Marin Cardenas
 
Antibody For Alzheimer Disease
Antibody For Alzheimer DiseaseAntibody For Alzheimer Disease
Antibody For Alzheimer DiseaseClaireJagodzinski
 
Possibility of Fullerene as Therapeutic Agent in Alzheimer's
Possibility of Fullerene as Therapeutic Agent in Alzheimer'sPossibility of Fullerene as Therapeutic Agent in Alzheimer's
Possibility of Fullerene as Therapeutic Agent in Alzheimer'ssharma93vidushi
 

Destacado (20)

Alzheimer disease (ad)
Alzheimer disease (ad)Alzheimer disease (ad)
Alzheimer disease (ad)
 
Alzheimer Disease
Alzheimer DiseaseAlzheimer Disease
Alzheimer Disease
 
what is Alzheimer disease
what is Alzheimer diseasewhat is Alzheimer disease
what is Alzheimer disease
 
Coursera work: Understanding the Brain: The Neurobiology of Everyday Life
Coursera work: Understanding the Brain: The Neurobiology of Everyday LifeCoursera work: Understanding the Brain: The Neurobiology of Everyday Life
Coursera work: Understanding the Brain: The Neurobiology of Everyday Life
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer disease
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer disease
 
Alzheimer\'s Disease
Alzheimer\'s DiseaseAlzheimer\'s Disease
Alzheimer\'s Disease
 
New treatment trends in alzheimer disease
New treatment trends in alzheimer diseaseNew treatment trends in alzheimer disease
New treatment trends in alzheimer disease
 
Alzheimer awareness
Alzheimer awarenessAlzheimer awareness
Alzheimer awareness
 
Alzheimer disease and treatment
Alzheimer disease and treatment Alzheimer disease and treatment
Alzheimer disease and treatment
 
Alzheimer Disease and Mind Function
Alzheimer Disease and Mind FunctionAlzheimer Disease and Mind Function
Alzheimer Disease and Mind Function
 
Alzheimer Disease: Where Do We Go From Here?
Alzheimer Disease: Where Do We Go From Here?Alzheimer Disease: Where Do We Go From Here?
Alzheimer Disease: Where Do We Go From Here?
 
Presentacion alzheimer psp 1ºev.
Presentacion alzheimer psp 1ºev.Presentacion alzheimer psp 1ºev.
Presentacion alzheimer psp 1ºev.
 
Alzheimer’s
Alzheimer’sAlzheimer’s
Alzheimer’s
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Proteins, medical utility, diagnosis and treatment in Alzheimer disease
Proteins, medical utility, diagnosis and treatment in Alzheimer disease Proteins, medical utility, diagnosis and treatment in Alzheimer disease
Proteins, medical utility, diagnosis and treatment in Alzheimer disease
 
Poster
PosterPoster
Poster
 
Antibody For Alzheimer Disease
Antibody For Alzheimer DiseaseAntibody For Alzheimer Disease
Antibody For Alzheimer Disease
 
Experimental study on alzhimer
Experimental study on alzhimerExperimental study on alzhimer
Experimental study on alzhimer
 
Possibility of Fullerene as Therapeutic Agent in Alzheimer's
Possibility of Fullerene as Therapeutic Agent in Alzheimer'sPossibility of Fullerene as Therapeutic Agent in Alzheimer's
Possibility of Fullerene as Therapeutic Agent in Alzheimer's
 

Similar a Alzheimer disease

AD GENETICS.pdf
AD GENETICS.pdfAD GENETICS.pdf
AD GENETICS.pdfAkreti1
 
Genetics of dementia
Genetics of dementiaGenetics of dementia
Genetics of dementiaAbeer Mahmoud
 
Awareness on Alzheimer's Disease.ppt
Awareness on Alzheimer's Disease.pptAwareness on Alzheimer's Disease.ppt
Awareness on Alzheimer's Disease.pptyellammakuna2
 
group 1 presentation.pptx
group 1 presentation.pptxgroup 1 presentation.pptx
group 1 presentation.pptxSalmanYare
 
Genetics of dementia 2017
Genetics of dementia 2017Genetics of dementia 2017
Genetics of dementia 2017Larry Baum
 
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptx
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptxALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptx
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptxsarathchandran951352
 
Early-Onset Alzheimer's Presentation
Early-Onset Alzheimer's PresentationEarly-Onset Alzheimer's Presentation
Early-Onset Alzheimer's PresentationJoelle Petrei
 
Recent advances in the management of alzheimers disease
Recent advances in the management of alzheimers diseaseRecent advances in the management of alzheimers disease
Recent advances in the management of alzheimers diseaseParthajyoti Neog
 
new gene and new target in alzheimer disease
new gene and new target in alzheimer diseasenew gene and new target in alzheimer disease
new gene and new target in alzheimer diseaseDr Surendra Khosya
 
alzheimer disease 2009 mucke.pdf
alzheimer disease 2009 mucke.pdfalzheimer disease 2009 mucke.pdf
alzheimer disease 2009 mucke.pdfPriyankaBhat30
 
ALZHEIMER DISEASE.pdf
ALZHEIMER DISEASE.pdfALZHEIMER DISEASE.pdf
ALZHEIMER DISEASE.pdfAmeena Kadar
 
Sneha Genetic Alzheimer-1.docx
Sneha Genetic Alzheimer-1.docxSneha Genetic Alzheimer-1.docx
Sneha Genetic Alzheimer-1.docxSneha Pandey
 
Deafness and hearing impairement
Deafness and hearing impairementDeafness and hearing impairement
Deafness and hearing impairementAyessa Mae Luna
 
2. late onset alzheimer disease
2. late onset alzheimer disease2. late onset alzheimer disease
2. late onset alzheimer diseaseFaco Garcia
 
Genetics in dementia
Genetics in dementiaGenetics in dementia
Genetics in dementiaRavi Soni
 
Genetics in Epilepsy.pptx
Genetics in Epilepsy.pptxGenetics in Epilepsy.pptx
Genetics in Epilepsy.pptxPramod Krishnan
 
Inborn errors of metabolism ppt
Inborn errors of metabolism pptInborn errors of metabolism ppt
Inborn errors of metabolism pptSree varshini
 

Similar a Alzheimer disease (20)

AD GENETICS.pdf
AD GENETICS.pdfAD GENETICS.pdf
AD GENETICS.pdf
 
Genetics of dementia
Genetics of dementiaGenetics of dementia
Genetics of dementia
 
Awareness on Alzheimer's Disease.ppt
Awareness on Alzheimer's Disease.pptAwareness on Alzheimer's Disease.ppt
Awareness on Alzheimer's Disease.ppt
 
group 1 presentation.pptx
group 1 presentation.pptxgroup 1 presentation.pptx
group 1 presentation.pptx
 
Genetics of dementia 2017
Genetics of dementia 2017Genetics of dementia 2017
Genetics of dementia 2017
 
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptx
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptxALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptx
ALZHEIMERS DEMENTIA-PATHOLOGY AND PATHOPHYSIOLOGY.pptx
 
Early-Onset Alzheimer's Presentation
Early-Onset Alzheimer's PresentationEarly-Onset Alzheimer's Presentation
Early-Onset Alzheimer's Presentation
 
Recent advances in the management of alzheimers disease
Recent advances in the management of alzheimers diseaseRecent advances in the management of alzheimers disease
Recent advances in the management of alzheimers disease
 
new gene and new target in alzheimer disease
new gene and new target in alzheimer diseasenew gene and new target in alzheimer disease
new gene and new target in alzheimer disease
 
alzheimer disease 2009 mucke.pdf
alzheimer disease 2009 mucke.pdfalzheimer disease 2009 mucke.pdf
alzheimer disease 2009 mucke.pdf
 
ALZHEIMER DISEASE.pdf
ALZHEIMER DISEASE.pdfALZHEIMER DISEASE.pdf
ALZHEIMER DISEASE.pdf
 
Genetics
GeneticsGenetics
Genetics
 
Sneha Genetic Alzheimer-1.docx
Sneha Genetic Alzheimer-1.docxSneha Genetic Alzheimer-1.docx
Sneha Genetic Alzheimer-1.docx
 
Alzheimer's disease
Alzheimer's diseaseAlzheimer's disease
Alzheimer's disease
 
Deafness and hearing impairement
Deafness and hearing impairementDeafness and hearing impairement
Deafness and hearing impairement
 
2. late onset alzheimer disease
2. late onset alzheimer disease2. late onset alzheimer disease
2. late onset alzheimer disease
 
Genetics in dementia
Genetics in dementiaGenetics in dementia
Genetics in dementia
 
Lorenzo' oil (Autosaved)
Lorenzo' oil (Autosaved)Lorenzo' oil (Autosaved)
Lorenzo' oil (Autosaved)
 
Genetics in Epilepsy.pptx
Genetics in Epilepsy.pptxGenetics in Epilepsy.pptx
Genetics in Epilepsy.pptx
 
Inborn errors of metabolism ppt
Inborn errors of metabolism pptInborn errors of metabolism ppt
Inborn errors of metabolism ppt
 

Más de mohammed Qazzaz (20)

Nocturnal Enuresis
Nocturnal EnuresisNocturnal Enuresis
Nocturnal Enuresis
 
‫أَيَّاً يَكُن
‫أَيَّاً يَكُن ‫أَيَّاً يَكُن
‫أَيَّاً يَكُن
 
DVT.. Deep vein thrombosis.
DVT.. Deep vein thrombosis.DVT.. Deep vein thrombosis.
DVT.. Deep vein thrombosis.
 
Croup
CroupCroup
Croup
 
Blood film
Blood filmBlood film
Blood film
 
Iron deficiency in children
Iron deficiency in childrenIron deficiency in children
Iron deficiency in children
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Epstein barr virus
Epstein barr virus Epstein barr virus
Epstein barr virus
 
Migraine
MigraineMigraine
Migraine
 
Breastfeeding
Breastfeeding Breastfeeding
Breastfeeding
 
Rickettsial diseases
Rickettsial diseasesRickettsial diseases
Rickettsial diseases
 
Herbal medicine
Herbal medicineHerbal medicine
Herbal medicine
 
Conjuctival diseases
Conjuctival diseasesConjuctival diseases
Conjuctival diseases
 
الاجهاض
الاجهاضالاجهاض
الاجهاض
 
Diabetic Ketoacidosis
Diabetic KetoacidosisDiabetic Ketoacidosis
Diabetic Ketoacidosis
 
lacrimal system anatomy and clinical
lacrimal system anatomy and clinicallacrimal system anatomy and clinical
lacrimal system anatomy and clinical
 
Enegry drink hazards
Enegry drink hazardsEnegry drink hazards
Enegry drink hazards
 
Herpes simplex virus
Herpes simplex virusHerpes simplex virus
Herpes simplex virus
 
Autism
AutismAutism
Autism
 
Vomiting
VomitingVomiting
Vomiting
 

Alzheimer disease

  • 2. In 1906 Dr. Alois Alzheimer was first to describe Alzheimer's illness. A progressive, degenerative illness that attacks the brain and results in impaired memory, thinking and behavior.
  • 3. Memory loss that affects job skills. Difficulty performing familiar tasks. Problems with language . Disorientation to time and place. Poor or decreased judgment. Problems with abstract thinking. Misplacing things . Changes in mood or behavior. Changes in personality.
  • 4. Forgetfulness . Social withdrawal . Hallucinations . Seizures . Death usually result from malnutrition , infection , heart disease
  • 5. AD is a pan ethnic , genetically heterogeneous disease Less than 5% of patients have an early-onset familial disease , 15-25% of patients have a late-onset familial disease and 75% of patients have a sporadic disease . 10% of familial AD exhibits autosomal dominant inheritance ; the reminder exhibits multifactorial inheritance .
  • 6. Early-onset AD is a rare form of AD, affecting only about 5 percent of all people who have AD. It develops in people ages 30 to 60. FAD is caused by a number of different gene mutations on chromosomes 21, 14, and 1, and each of these mutations causes abnormal proteins to be formed.
  • 7. Mutations on chromosome 21 cause the formation of abnormal amyloid precursor protein (APP). A mutation on chromosome 14 causes abnormal presenilin 1 to be made, and a mutation on chromosome 1 leads to abnormal presenilin 2.
  • 8. Even if only one of these mutated genes is inherited from a parent, the person will almost always develop early-onset AD. This inheritance pattern is referred to as “autosomal dominant” inheritance. In other words, offspring in the same generation have a 50/50 chance of developing FAD if one of their parents had it.
  • 9. developing after age 60. genetics of AD have found that the mutations seen in early-onset AD are not involved in this form of the disease. Both familial AD and sporadic late-onset AD are strongly associated with Apo lipoprotein E (APOE) gene found on chromosome 19 APOE comes in several different forms, or alleles. Three forms—APOE ε2, APOE ε3, and APOE ε4—occur most frequently.
  • 10. APOE ε4 occurs in about 40 percent of all people who develop late-onset AD. and is present in about 25 to 30 percent of the population. People with AD are more likely to have an APOE ε4 allele than people who do not develop AD. However, many people with AD do not have an APOE ε4 allele.
  • 11. APP undergoes endoproteolytic cleavage in the to produce a peptide of 40 amino acid (Aβ40) the function of Aβ40 is unknown . In contrast , cleavage of APP in the endoplasmic reticulum produce a peptide of 42 or 43 Amino acid (Aβ42/ Aβ43) .and its neurotoxic substance .
  • 12. Patients with AD have a significant increase in (Aβ42/ Aβ43) aggregates within the brain Mutation in APP PSEN1 and PSEN2 increase the production of (Aβ42/43) . 1% of all AD cases occur in patients with down syndrome . Who overexpress APP. The role of ε4 is unclear .
  • 13. Cortical atrophy . Neurodegeneration in cholinergic neurons of hippocampus . Extracellular neuritic plaques . Intraneuronal neurofibrillary tangles . Amyloid deposits in the wall of cerebral arteries .
  • 14. An AD plaque An AD tangle
  • 15. Beta-amyloid Plaques Amyloid precursor protein (APP) is the precursor to amyloid plaque. 1. APP sticks through the neuron membrane. 2. Enzymes cut the APP into fragments of protein, including beta- amyloid. 3. Beta-amyloid fragments come together in clumps to form plaques.
  • 16.
  • 17. Mutation in PSEN1 are fully penetrant and usually cause rapidly progressive disease with mean onset at 45 . Mutation in APP are fully penetrant and usually cause a rate of AD progression similar to that of late-onset AD with range onset of 45 to 75 . Mutation in PSEN2 are not fully penetrant and usually cause slowly progressive disease with onset ranging from 40 to 57 .
  • 18. Increase the cholinergic activity •cholesterol-lowering drugs •anti-oxidants (vitamins) and folic acid •anti-inflammatory drugs •substances that prevent formation of beta-amyloid plaques •nerve growth factor to keep neurons healthy
  • 19. Old age Family history Female gender Down syndrome